(24/7 MARKET NEWS) – Context Therapeutics Inc. (Nasdaq: CNTX) announced, this morning, that it is collaborating with Lonza to manufacture CTIM-76, Context’s clinical development candidate. CTIM-76 is a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody targeting CLDN6 positive tumors.
Context Therapeutics is trading higher on much stronger than average trading volume at $1.1109, up $0.3496 (+45.92%), on 12.2 million shares traded.
Its 52-week range is $0.60 to $2.79. It has an interesting chart and, if it can break through the $1.50 resistance level, on strong volume, it could try to challenge the $2 level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
